BioSpace News Archive

Metadeq Diagnostics, Inc. announced the presentation of three posters at the EASL SLD Summit 2023 in Prague, Czech Republic.

NeuroSense Therapeutics Ltd. announced that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise status by the European Medicines Agency, which offers significant benefits leading up to and following drug regulatory approval.

RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX™ biology-guided radiotherapy.

De La Vina Surgicenter in Santa Barbara, CA, and medical device and technology company Lazurite® announced that De La Vina is the first healthcare center in Southern California to adopt Lazurite’s new ArthroFree® Wireless Surgical Camera System.

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.

The Menarini Group and Stemline Therapeutics Inc. announced that the European Commission has approved ORSERDU® as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor ‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.

Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.

Hearing the sound of a newborn’s wail can trigger the release of oxytocin, a brain chemical that controls breast-milk release in mothers, a new study in rodents shows.

Bloomage Biotech has achieved a breakthrough in its research on the varying efficacies of Hyaluronic Acid (HA) molecules of different weight This fundamental study by Bloomage Biotech has resulted in an enzyme degradation technology that can accurately control the molecular size of HA between 400Da and 4000kDa.

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: REGN) to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four.